Table 2.
Details for EC subgroups.
| Variable | EAC N (%) | nEAC N (%) | ESCC N (%) | nESCC N (%) |
|---|---|---|---|---|
| Gender | ||||
| Male | 68 (81.0) | 100 (85.5) | 21 (65.6) | 36 (72.0) |
| Female | 16 (19.0) | 17 (14.5) | 11 (34.4) | 14 (28.0) |
| UICC stage | ||||
| 0 | 6 (7.1) | 8 (6.8) | 2 (6.3) | 11 (22.0) |
| 1 | 51 (60.7) | 12 (10.3) | 7 (21.9) | 5 (10.0) |
| 2 | 17 (20.2) | 35 (29.9) | 11 (34.4) | 17 (34.0) |
| 3 | 9 (10.7) | 59 (50.4) | 12 (37.5) | 17 (34.0) |
| 4 | 1 (1.2) | 3 (2.6) | 0 (0.0) | 0 (0.0) |
| Adjuvant therapy | ||||
| Yes | 1 (1.2) | 24 (20.5) | 2 (6.3) | 3 (6.0) |
| No | 83 (98.8) | 93 (79.5) | 30 (93.7) | 47 (94.0) |
| Surgical approach | ||||
| One-stage | 29 (34.5) | 20 (17.1) | 0 (0.0) | 1 (2.0) |
| Two-stage | 55 (65.5) | 97 (82.9) | 32 (100) | 49 (98.0) |
| CRP > 1 ∗ | ||||
| Yes | 11 (13.3) | 19 (16.7) | 7 (21.9) | 17 (34.0) |
| No | 72 (86.7) | 95 (83.3) | 25 (78.1) | 33 (66.0) |
| Alb < 35 ∗ | ||||
| Yes | 10 (12.0) | 14 (12.2) | 1 (3.1) | 7 (14.0) |
| No | 73 (88.0) | 101 (87.8) | 31 (96.9) | 43 (86.0) |
| GPS ∗ | ||||
| 0 | 64 (77.1) | 86 (75.4) | 25 (78.1) | 32 (64.0) |
| 1 | 17 (20.5) | 23 (20.2) | 6 (18.8) | 12 (24.0) |
| 2 | 2 (2.4) | 5 (4.4) | 1 (3.1) | 6 (12.0) |
| mGPS ∗ | ||||
| 0 | 72 (86.8) | 95 (83.3) | 25 (78.1) | 33 (66.0) |
| 1 | 9 (10.8) | 14 (12.3) | 6 (18.8) | 11 (22.0) |
| 2 | 2 (2.4) | 5 (4.4) | 1 (3.1) | 6 (12.0) |
| C/A ratio > 0.95 ∗ | ||||
| Yes | 4 (4.8) | 6 (5.3) | 1 (3.1) | 6 (12.0) |
| No | 79 (95.2) | 108 (94.7) | 31 (96.9) | 44 (88.0) |
∗In four patients, preoperative CRP and/or albumin was not available. EC: esophageal cancer; EAC: esophageal adenocarcinoma; nEAC: neoadjuvant-treated esophageal cancer; ESCC: esophageal squamous cell carcinoma; nESCC: neoadjuvant-treated esophageal squamous cell carcinoma; UICC: Union for International Cancer Control; CRP > 1: preoperative serum C-reactive protein >1 mg/dl; Alb < 35: preoperative serum albumin <35 g/l; GPS: glasgow prognostic score; mGPS: modified Glasgow prognostic score; C/A ratio: ratio from preoperative serum CRP and albumin.